{"schema_version":"secwatch.filing_event.v1","accession":"0000200406-25-000201","form_type":"8-K","ticker":"JNJ","cik":"0000200406","company_name":"JOHNSON & JOHNSON","filed_at":"2025-10-14T23:59:59+00:00","discovered_at":"2026-05-14T18:02:41.264827+00:00","generated_at":"2026-05-17T03:59:47.936785+00:00","sec_items":["2.02","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"JNJ reports Q3 adjusted EPS $2.80; plans to spin off Orthopaedics as DePuy Synthes","bullets":["Q3 revenue $23,993M (+6.8% YoY); GAAP EPS $2.12, adjusted EPS $2.80 (+15.7% YoY).","Innovative Medicine sales $15,563M (+6.8% operational); MedTech sales $8,430M (+6.8% operational).","Intends to separate Orthopaedics business into standalone DePuy Synthes; FY2024 ortho sales ~$9.2B.","Target completion in 18-24 months; Namal Nawana appointed Worldwide President of DePuy Synthes.","Separation aims to shift MedTech portfolio to higher-growth/margin markets; JNJ retains focus on six growth areas."],"urls":{"canonical":"https://secwatch.observer/filing/0000200406-25-000201","json":"https://secwatch.observer/filing/0000200406-25-000201.json","markdown":"https://secwatch.observer/filing/0000200406-25-000201.md","text":"https://secwatch.observer/filing/0000200406-25-000201.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/200406/000020040625000201/0000200406-25-000201-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/200406/000020040625000201/jnj-20251014.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T03:59:47.936785+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}